Other equities research analysts also recently issued research reports about the company. B. Riley reissued a buy rating and issued a $11.25 price objective on shares of Cytosorbents Corp in a report on Wednesday, March 1st. HC Wainwright increased their price objective on Cytosorbents Corp from $11.50 to $13.00 and gave the company a buy rating in a report on Monday, March 6th. Finally, Aegis reissued a buy rating on shares of Cytosorbents Corp in a report on Tuesday, March 7th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $15.65.
Shares of Cytosorbents Corp (NASDAQ:CTSO) opened at 5.425 on Wednesday. The company’s market cap is $138.46 million. The firm has a 50-day moving average of $5.49 and a 200 day moving average of $5.61. Cytosorbents Corp has a one year low of $3.87 and a one year high of $6.90.
TRADEMARK VIOLATION NOTICE: “Maxim Group Reaffirms “Buy” Rating for Cytosorbents Corp (CTSO)” was originally reported by Mideast Time and is the property of of Mideast Time. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.mideasttime.com/maxim-group-reaffirms-buy-rating-for-cytosorbents-corp-ctso/1589262.html.
An institutional investor recently raised its position in Cytosorbents Corp stock. Advisor Group Inc. raised its position in shares of Cytosorbents Corp (NASDAQ:CTSO) by 1.1% during the third quarter, according to its most recent filing with the SEC. The firm owned 305,145 shares of the company’s stock after buying an additional 3,300 shares during the period. Advisor Group Inc. owned approximately 1.20% of Cytosorbents Corp worth $1,953,000 as of its most recent SEC filing. 6.07% of the stock is currently owned by hedge funds and other institutional investors.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.